Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Austin G Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-ichi Nishimura, Christopher J Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jens Peter Panse, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Maria Risitano, Jong Wook Lee

Blood blood.2024026299.

https://doi.org/10.1182/blood.2024026299

Published: 2024

Includes: Supplemental data

Journal Articles

PRUNE1-IGF2BP3 Forms a Positive Feedback Loop By Stabilizing SOX4 mRNA in an m6A-Denpendent Manner to Promote Multiple Myeloma with 1q21 Gain

Yawen Wang, Peng Liu, Jiadai Xu, Panpan Li

Blood (2024) 144 (Supplement 1): 6844.

https://doi.org/10.1182/blood-2024-201516

Published: 2024

Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1661.1.

https://doi.org/10.1182/blood-2024-198728

Published: 2024

Journal Articles

Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Jiadai Xu, Peng Liu

Blood (2024) 144 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2024-198093

Published: 2024

Journal Articles

Double-Hit/Triple-Hit Myeloma: An Adverse Prognostic Factor That Can be Overcome By Minimal Residual Disease Negativity

Yang Yang, Wenjing Wang, Liang Ren, Yawen Wang, Aziguli Maihemaiti, Tianwei Lan, Chi Zhou, Panpan Li, Pu Wang, Jing Li, Jiadai Xu, Tianhong Xu, Fei-fei Chen, Peng Liu

Blood (2024) 144 (Supplement 1): 6956.

https://doi.org/10.1182/blood-2024-207788

Published: 2024

Journal Articles

YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

Sahitya Saka, Yinghua Wang, Peng Liu, Audrey Kopp, Michael Atchison, Marjorie Brand, Xuan Pan

Blood (2024) 144 (Supplement 1): 2657.

https://doi.org/10.1182/blood-2024-203772

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Caroline Piatek, Jong Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Mohammed Mahdi, Peng Liu, Karl-Johan Myren, Andrew Messali, Flore Sicre de Fontbrune, Jens Panse, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2024-199506

Published: 2024

Journal Articles

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Koichi R. Katsumura, Peng Liu, Jeong-Ah Kim, Charu Mehta, Vu L. Tran, Mabel M. Jung, Kirby D. Johnson, Emery H. Bresnick

Blood (2024) 144 (Supplement 1): 4091.

https://doi.org/10.1182/blood-2024-208365

Published: 2024

Journal Articles

Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques

Jing Li, Yang Yang, Chenqi Yu, Yuxia Yang, Peng Liu

Blood (2024) 144 (Supplement 1): 4700.

https://doi.org/10.1182/blood-2024-207188

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics

Mabel M. Jung, Koichi R. Katsumura, Siqi Shen, Vu L. Tran, Peng Liu, Kirby D. Johnson, Sunduz Keles, Emery H. Bresnick

Blood (2024) 144 (Supplement 1): 1325.

https://doi.org/10.1182/blood-2024-210730

Published: 2024

Journal Articles

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Wenjing Wang, Jing Li, Mengyuan Li, Xiao He, LI Bao, Xiaoqiong Tang, Hua Xue, Jianmei Xu, Liye Zhong, Peng Liu

Blood (2024) 144 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2024-207888

Published: 2024

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Exclusive Benefits of Sustained MRD-Negative in High-Risk Multiple Myeloma

Liang Ren, Tianhong Xu, Wenjing Wang, Yang Yang, Yawen Wang, Aziguli Maihemaiti, Tianwei Lan, Panpan Li, Chi Zhou, Pu Wang, Peng Liu

Blood (2023) 142 (Supplement 1): 6663.

https://doi.org/10.1182/blood-2023-172450

Published: 2023

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

Deletion of the Artery Specific Enhancer Promotes B Cell and Impairs T Cell Development from the Hemogenic Endothelium

Saritha S. D'souza, Akhilesh Kumar, Yoon Jung Choi, Samuel Dettle, Isla Emmen, Portia Smith, Divine M. Sedzro, Ho Sun Jung, Peng Liu, Igor Slukvin

Blood (2023) 142 (Supplement 1): 1299.

https://doi.org/10.1182/blood-2023-174748

Published: 2023

Journal Articles

The Mechanism Underlying Lenalidomide-Induced Thrombosis Susceptibility

Panpan Li, Bei Xu, Jiadai Xu, Yawen Wang, Yanyan Xu, Chen Chen, Peng Liu

Blood (2023) 142 (Supplement 1): 6505.

https://doi.org/10.1182/blood-2023-185515

Published: 2023

Journal Articles

Clinical Implication of Minimal Residual Disease By Multiparameter Flow Cytometry in Light Chain Amyloidosis

Tianhong Xu, Jing Li, Yang Yang, Wenjing Wang, Pu Wang, Chenqi Yu, Peng Liu

Blood (2023) 142 (Supplement 1): 6770.

https://doi.org/10.1182/blood-2023-184754

Published: 2023

NARROW

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

PRUNE1-IGF2BP3 Forms a Positive Feedback Loop By Stabilizing SOX4 mRNA in an m6A-Denpendent Manner to Promote Multiple Myeloma with 1q21 Gain

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Double-Hit/Triple-Hit Myeloma: An Adverse Prognostic Factor That Can be Overcome By Minimal Residual Disease Negativity

YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Exclusive Benefits of Sustained MRD-Negative in High-Risk Multiple Myeloma

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Deletion of the Artery Specific Enhancer Promotes B Cell and Impairs T Cell Development from the Hemogenic Endothelium

The Mechanism Underlying Lenalidomide-Induced Thrombosis Susceptibility

Clinical Implication of Minimal Residual Disease By Multiparameter Flow Cytometry in Light Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only